Vizimpro patent expiry in 2026 is uncertain, as patent protections for drugs are complex and can be extended through various mechanisms.
When does Vizimpro's core patent protection end?
The primary patent for Vizimpro, also known as dacomitinib, is expected to expire around 2026 [1]. However, this date can be affected by factors like patent extensions and other intellectual property strategies.
Can patent life be extended for Vizimpro?
Yes, patent terms for drugs can be extended through mechanisms such as patent term restoration, which compensates for time lost during the regulatory review process. Additional patents may also cover different aspects of the drug, such as formulation or manufacturing processes, which could extend market exclusivity beyond the core patent expiry [1].
What happens when Vizimpro's patents expire?
Once the relevant patents expire and any remaining exclusivity periods conclude, generic versions of Vizimpro could become available. This typically leads to a significant decrease in the drug's price due to competition from manufacturers of generic alternatives [2].
Who manufactures Vizimpro?
Vizimpro is manufactured by Pfizer Inc. [3].
Are there other drugs like Vizimpro?
Vizimpro is a tyrosine kinase inhibitor (TKI) used to treat non-small cell lung cancer (NSCLC) with specific EGFR mutations. Other TKIs in this class include gefitinib (Iressa), erlotinib (Tarceva), afatinib (Gilotrif), and osimertinib (Tagrisso). Each of these drugs has its own patent and exclusivity timelines [4].
How does Vizimpro's patent situation compare to other lung cancer drugs?
The patent expiry dates and strategies for other lung cancer drugs vary. For instance, some EGFR inhibitors have already faced or are facing generic competition, while newer generations of TKIs may have longer patent protections. A detailed analysis of specific patent landscapes for each drug is available through resources like DrugPatentWatch.com [1].
Where can I find more information on drug patents?
Detailed information on drug patents, including expiry dates, extensions, and potential challenges, can be found on DrugPatentWatch.com [1].
*
**Sources
1. https://drugpatentwatch.com/
2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3714264/
3. https://www.pfizer.com/products/product-detail/vizimpro
4. https://www.cancer.gov/about-cancer/treatment/drugs/nsclc-tyrosine-kinase-inhibitors